mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

View original at finance.yahoo.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Mereo BioPharma Group plc Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Partnering discussions around alvelestat in AATD-LD are continuing to advance on multiple fronts

    60% confidence

  • Revised financial runway into mid-2027 enables potential delivery of several key milestones during 2026

    60% confidence

  • āshibio plans to initiate a Phase 2 trial of vantictumab in osteopetrosis in the second half of 2026

    60% confidence

  • Setrusumab demonstrated statistically significant improvements in bone mineral density and compelling reductions in vertebral fractures

    60% confidence

  • Phase 3 Orbit and Cosmic studies did not achieve statistical significance on primary endpoints of fracture reduction

    60% confidence

  • Data from setrusumab studies may provide basis for engagement with regulatory agencies despite missing primary endpoints

    60% confidence

  • Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab in osteogenesis imperfecta are ongoing

    60% confidence

  • Existing cash and cash equivalents will enable funding of operations into mid-2027

    60% confidence

  • There are no FDA or EMA therapies approved specifically for osteogenesis imperfecta

    60% confidence

  • Single Phase 3 trial enrolling approximately 220 AATD-LD patients will support regulatory submissions in both U.S. and Europe

    60% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights — Source | Via News | fr.VIA.NEWS